Trial	Primary outcome	Secondary outcomes	Safety outcomes
ORCHID	COVID Ordinal Outcomes Scale on Study Day 15	 Time to recovery, defined as time to reaching level 5, 6, or 7 on the COVID Outcomes Scale, which is the time to the earlier of final liberation from supplemental oxygen or hospital discharge All-location, all-cause 14-day mortality (assessed on Study Day 15) All-location, all-cause 28-day mortality (assessed on Study Day 29) COVID Ordinal Outcomes Scale on Study Day 3 COVID Ordinal Outcomes Scale on Study Day 8 COVID Ordinal Outcomes Scale on Study Day 29 Composite of death or receipt of ECMO through Day 28 Oxygen-free days through Day 28 Vasopressor-free days through Day 28 ICU-free days through Day 28 Hospital-free days through Day 28 	 Seizure Atrial or ventricular arrhythmia Cardiac arrest Elevation in aspartate, aminotransferase, or alanine aminotransferase to twice the local upper limit of normal Acute pancreatitis Acute kidney injury Receipt of renal replacement therapy
WU352	Time (hours) from randomization to recovery defined as (1) absence of fever, as defined as at least 48 hours since last temperature ≥38.0°C without the use of fever-reducing medications AND (2) absence of symptoms of greater than mild severity for 24 hours AND (3) not requiring supplemental oxygen beyond pre-COVID baseline AND (4) freedom from mechanical ventilation or death	 Time to resolution of fever defined as at least 48 hours since last temperature ≥38.0°C without the use of fever-reducing medications Time to improvement in symptoms (scored as mild or absent and remained so for 24 hour) Mean improvement in symptom from baseline Duration of hospitalization Proportion requiring supplementary oxygen (above baseline usage) at any time during follow-up Duration (days) of requirement for supplementary oxygen Proportion requiring ICU admission at any time during follow-up Ventilator free days All-cause mortality 	 Serious Adverse Events that occur within 6 weeks after randomization Unanticipated problem (UP) Unexpected adverse drug event (UADE)
NCT04335552 (Duke)	WHO ordinal scale measured at 14 days after enrollment	 Death during the index hospitalization Number of days on mechanical ventilation Proportion of patients not receiving mechanical ventilation at baseline who progress to requiring mechanical ventilation 	 Arrhythmias (ventricular) Hepatic failure Bone marrow failure Aplastic anemia

S4 Table. Primary, Secondary, and Safety Outcomes

Trial	Primary outcome	Secondary outcomes	Safety outcomes
		during the index hospitalization • WHO ordinal scale measured at 28 days after enrollment • Hospital length of stay in days for the index hospitalization • Days of fever (temperature ≥38.0) after randomization • Days on supplemental oxygen after randomization • All-cause study medication discontinuation • Drug-associated adverse events of special interest	 Prolonged QT interval Angioedema Exfoliative dermatitis Acute generalized exanthematous pustulosis (AGEP) Psychosis Suicidal ideation Seizure SAEs that occur between initial dose of study medication and day 14
TEACH	A severe disease progression composite endpoint defined by the occurrence of any of the following: mortality, ICU admission, invasive mechanical ventilation, ECMO, and/or hypotension requiring vasopressor support by the 14- day post-treatment evaluation	 Composite outcome (mortality, ICU admission, invasive mechanical ventilation, ECMO, and/or hypotension requiring vasopressor support) at 30 days Individual components of the composite endpoint (mortality, ICU admission, invasive mechanical ventilation, ECMO, and/or hypotension requiring vasopressor support) by EOT, PTE, and 30 days of treatment Hospital length of stay Days of fever Days of non-invasive ventilator use Days of non-rebreather mask oxygen supplementation Cytokine release syndrome grading scale Percentage of subjects reporting each severity score on 8-point ordinal scale D1 and EOT SARS-CoV-2 viral eradication from nasopharyngeal specimens at EOT, measured by RT-PCR Change from baseline AST, ALT, creatinine, glucose, white blood cell count, lymphocyte percentage, hemoglobin, platelets, total bilirubin, LDH, CRP, and IL-6 at EOT 	• Primary Safety Composite: Cumulative incidence of SAEs through day 30, grade 3 or 4 AEs through day 30, and/or discontinuation of therapy (for any reason)
COVID MED	NIAID COVID-19 Ordinal Severity Score	 Mortality Hospital/ICU/ventilator length of stay (LOS) Reason for ventilator discontinuation (if applicable) Antibiotics use Symptoms-based COVID-19 severity score 	 Complications AEs/SAEs
HAHPS	WHO COVID Ordinal Outcomes Scale at 14 days	 Hospital-free days at 28 days (calculated as a worst-rank ordinal) Ventilator-free days at 28 days (calculated as a worst-rank ordinal) 	 Counts (proportions) of adverse events Those listed in the package insert for hydroxychloroquine and azithromycin QT interval

Trial	Primary outcome	Secondary outcomes	Safety outcomes
		 ICU-free days at 28 days (calculated as a worst-rank ordinal) Time to a 1-point decrease in the WHO ordinal recovery score 	• Arrythmia
NCT04344444 (University Medical Center New Orleans)	Composite incidence of death, transfer to ICU, initiation of mechanical ventilation, or initiation of ECMO	 Toxicities of the drugs SARS-CoV2 viral load over time Length of hospital stay Number of ICU days Rate of readmission after hospital discharge Duration of symptoms 	 AEs monitored daily, including drug toxicity. QTc monitoring via telemetry
OAHU-COVID19	Clinical status (on a 7-point ordinal scale) at day 15	 Time to an improvement of one category from admission using an ordinal scale Subject clinical status using ordinal scale at days 3, 5, 8, 11, and 28 Mean change in the ordinal scale from baseline to days 3, 5, 8, 11, 15, and 28 from baseline The time to discharge or to a National Early Warning Score (NEWS) of ≤2 and maintained for 24 hours, whichever occurs first Oxygenation free days in the first 28 days Incidence and duration of new oxygen use during the study Ventilator-free days in the first 28 days Incidence and duration of new mechanical ventilation use during hospitalization Duration of hospitalization (days) 	 28-day mortality Cumulative incidence of serious adverse events (SAEs) through 28-day follow-up Cumulative incidence of Grade 3 and 4 adverse events Discontinuation of hydroxychloroquine for any reason Changes in WBC, Hb, Plt, Creat, CrCl, Gluc, Tot Bili, ALT, AST over time